Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
08:30pm, Thursday, 05'th Nov 2020
Codexis (CDXS) delivered earnings and revenue surprises of 37.50% and 22.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Codexis to Hold Third Quarter 2020 Conference Call on November 5
07:00am, Thursday, 29'th Oct 2020
REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after ma
Codexis Dodges Coronavirus Slowdown in Q2
12:33pm, Tuesday, 11'th Aug 2020
R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.
Codexis Reports Second Quarter 2020 Financial Results
08:05pm, Thursday, 06'th Aug 2020
Revenues increased 21% to $15 million; 72% rise in R&D revenue included a significant contribution from the Takeda biotherapeutics partnership Conference call with slides begins at 4:30 p.m. Eastern
Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors
11:00am, Thursday, 06'th Aug 2020
Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors Dr. Jennifer L. AakerREDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering co
Sumitomo Mitsui Trust Holdings Inc. Has $9.12 Million Position in Codexis, Inc. (NASDAQ:CDXS)
07:36am, Wednesday, 05'th Aug 2020
Sumitomo Mitsui Trust Holdings Inc. reduced its holdings in Codexis, Inc. (NASDAQ:CDXS) by 38.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 800,367 shares of the
Codexis to Hold Second Quarter 2020 Conference Call on August 6
11:00am, Thursday, 30'th Jul 2020
REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after m
Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline
04:33pm, Tuesday, 28'th Jul 2020
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research Downgrades Codexis (NASDAQ:CDXS) to Sell
01:38am, Friday, 26'th Jun 2020
Codexis (NASDAQ:CDXS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Code
AVID BIOSERVICES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) | MarketScreener
09:21pm, Thursday, 25'th Jun 2020Codexis (CDXS) Gets a Buy Rating from H.C. Wainwright - Markets
10:21am, Wednesday, 24'th Jun 2020
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price
Avid Bioservices Names Nicholas Green as President and Chief Executive Officer | MarketScreener
12:06pm, Tuesday, 23'rd Jun 2020Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis
11:00am, Tuesday, 23'rd Jun 2020
Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announce a par
A New Way Of Making DNA Is About To Revolutionize The Biotech Industry
12:00am, Tuesday, 23'rd Jun 2020
Has the next biotech unicorn just been minted? Two California firms are focused on a radical new way of writing DNA to create everything from COVID-19 antibodies to high-density data storage.
